Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC8A1 | P32418 | 7/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794039 | 1.00 | SLC8A1 (0.32) | SLC8A1HIF1AFFAR4FFAR1DGAT1 | |
| SCHEMBL6031402 | 1.00 | SLC8A1 (0.32) | SLC8A1HIF1AFFAR4FFAR1DGAT1 | |
| SCHEMBL6785471 | 1.00 | SLC8A1 (0.32) | SLC8A1HIF1AFFAR4FFAR1DGAT1 | |
| SCHEMBL6481175 | 0.93 | BACE1 (0.36) | SLC8A1BACE1BACE2 | |
| SCHEMBL6494200 | 0.89 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL6032368 | 0.86 | DRD2 (0.35) | FFAR4FFAR1 | |
| SCHEMBL6481179 | 0.86 | AAK1 (0.32) | SLC8A1HIF1A | |
| SCHEMBL6027687 | 0.86 | FFAR4 (0.33) | SLC8A1FFAR4FFAR1 | |
| SCHEMBL6027685 | 0.86 | FFAR4 (0.33) | SLC8A1FFAR4FFAR1 | |
| SCHEMBL6790914 | 0.82 | FFAR4 (0.35) | SLC8A1FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699860-B2 | ADRENERGIC BLOCKING AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-03-02 | — | — | US | disclosed |
| EP-1343778-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| WO-2002048134-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | SLC8A1 2595/4885HIF1A 3090/4885FFAR4 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.